# Clinical trial results:
# Phase II trial of weekly Carboplatin-Paclitaxel adjuvant chemotherapy after intensity modulated extended-field chemoradiation in the treatment of locally advanced cervical cancer with para-aortic positive nodes

## Summary

| | |
|---|---|
| EudraCT number | 2018-001752-35 |
| Trial protocol | FR |
| Global end of trial date | 20 June 2025 |

**Results information**

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 28 February 2026 |
| First version publication date | 28 February 2026 |

## Trial information

**Trial identification**

| | |
|---|---|
| Sponsor protocol code | 2018-06 |

**Additional study identifiers**

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04016142 |
| WHO universal trial number (UTN) | - |

Notes:

**Sponsors**

| | |
|---|---|
| Sponsor organisation name | Centre Oscar Lambret |
| Sponsor organisation address | 3 Rue Frédéric Combemale, Lille, France, 59000 |
| Public contact | DRCI Sponsor Unit, Centre Oscar Lambret, +33 320295918, promotion@o-lambret.fr |
| Scientific contact | DRCI Sponsor Unit, Centre Oscar Lambret, +33 320295918, promotion@o-lambret.fr |

Notes:

**Paediatric regulatory details**

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 26 November 2025 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 31 January 2025 |
| Global end of trial reached? | Yes |
| Global end of trial date | 20 June 2025 |
| Was the trial ended prematurely? | Yes |

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the efficacy of adjuvant chemotherapy per Carboplatin-Paclitaxel administrated in adjuvant situation after concomitant radio-chemotherapy in terms of Progression Free Survival (PFS) for patients treated for a cervical cancer locally advanced presenting positive lombo-aortic lymph nodes

Protection of trial subjects:

This study was conducted in accordance with the ethical principles of the 1964 Helsinki declaration, revised in 2013 and 2024 in Fortaleza, with the rules of Good Clinical Practice (GCP) defined by the International Conference on Harmonization (ICH-E6, 17/7/96)), and all applicable laws et regulations. The clinical trial did not begin before approval of the Ethics Committees and authorization by competent authorities concerned.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 15 June 2020 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | France: 21 |
| Worldwide total number of subjects | 21 |
| EEA total number of subjects | 21 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 18 |
| From 65 to 84 years | 3 |

| | |
|---|---|
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details:

The trial was opened in 6 french centers. 21 patients were enrolled in 2 centers from 15/06/2020 and 04/07/2023 in the part I of the study. Among these patients, 14 patients were enrolled in the part II of the study.

### Pre-assignment

Screening details:

A total of 45 patients were planned in the study protocol, but only 21 patients were actually enrolled due to low recruitment.

### Period 1

| | |
|---|---|
| Period 1 title | Part 1: standard concomitant RT-CT |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

### Arms

| | |
|---|---|
| **Arm title** | Population included in part I |

Arm description:

Standard treatment

| | |
|---|---|
| Arm type | First part of the study (standard treatment) |
| Investigational medicinal product name | Cisplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Sterile concentrate |
| Routes of administration | Intravenous use |

Dosage and administration details:

Weekly cisplatin (40 mg/m²)

| **Number of subjects in period 1** | Population included in part I |
|---|---|
| Started | 21 |
| Completed | 14 |
| Not completed | 7 |
| Patient refusal | 2 |
| Standard treatment not received in totality | 1 |
| Adverse event, non-fatal | 3 |
| Progression | 1 |

## Period 2

| | |
|---|---|
| Period 2 title | Part 2: experimental adjuvant CT |
| Is this the baseline period? | No |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

## Arms

| **Arm title** | Population included in part II |
|---|---|

Arm description:

Experimental treatment

| | |
|---|---|
| Arm type | Second part of the study (experimental treatment) |
| Investigational medicinal product name | Paclitaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for injection/infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

80 mg/m² (+/- 5% tolerated)
Maximum dose = 160mg (corresponding to a BSA = 2.0m²)

| | |
|---|---|
| Investigational medicinal product name | Carboplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

AUC2 * (GFR + 25) mg (+/- 5% tolerated)
Maximum dose = 270 mg (corresponding to a GFR of 110ml/min)

| **Number of subjects in period 2** | Population included in part II |
|---|---|
| Started | 14 |
| Completed | 14 |

## Baseline characteristics

### Reporting groups

| Reporting group title | Part 1: standard concomitant RT-CT |
|---|---|

Reporting group description: -

| Reporting group values | Part 1: standard concomitant RT-CT | Total | |
|---|---|---|---|
| Number of subjects | 21 | 21 | |
| Age categorical<br>Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 18 | 18 | |
| From 65-84 years | 3 | 3 | |
| 85 years and over | 0 | 0 | |
| Age continuous<br>Units: years | | | |
| median | 52 | | |
| full range (min-max) | 25 to 77 | - | |
| Gender categorical<br>Units: Subjects | | | |
| Female | 21 | 21 | |
| Male | 0 | 0 | |

## End points

### End points reporting groups

| | |
|---|---|
| Reporting group title | Population included in part I |
| Reporting group description: Standard treatment | |
| Reporting group title | Population included in part II |
| Reporting group description: Experimental treatment | |

### Primary: PFS (progression-free survival)

| | |
|---|---|
| End point title | PFS (progression-free survival)[1] |
| End point description: | |
| End point type | Primary |
| End point timeframe: PFS is estimated from the date of inclusion in the part II of the trial to the date of first progression or relapse (local, lymph nodes or metastatic) or death whatever the cause. Patients alive without progression at the date of last news are censored | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The study was prematurely ended due to lack of recrtuitment. No formal statistical comparison has been performed.

| End point values | Population included in part II | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: 2-years PFS rate in % | | | | |
| number (confidence interval 95%) | 71.4 (40.6 to 88.2) | | | |

### Statistical analyses

No statistical analyses for this end point

### Secondary: OS (overall survival)

| | |
|---|---|
| End point title | OS (overall survival) |
| End point description: | |
| End point type | Secondary |
| End point timeframe: OS is estimated from the date of inclusion in the part II of the trial to the date of death whatever the cause. Patients alive at the date of last news are censored | |

| End point values | Population included in part II | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: 2-years OS rate in % | | | | |
| number (confidence interval 95%) | 91.7 (53.9 to 98.8) | | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: MFS (metastatic-free survival)

| End point title | MFS (metastatic-free survival) |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

MFS is estimated from the date of inclusion in the part II until the date of first metastatic progression or death whatever the cause. Patients alive without metastatic progression at the date of last news are censored at this date

| End point values | Population included in part II | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: 2-years MFS rate in % | | | | |
| number (confidence interval 95%) | 78.6 (47.2 to 92.5) | | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Feasability

| End point title | Feasability |
|---|---|

End point description:

The number of cycles will be recorded

| End point type | Secondary |
|---|---|

End point timeframe:

During the experimental treatment

| **End point values** | Population included in part II | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: Number of chemotherapy cycles started | 14 | | | |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

For the 2nd part of the study, all AE are reported up to 30 days after the end of adjuvant chemotherapy, until progression if any. Then, only AE possibly related to chemotherapy or radiation therapy are collected, up to 5 years after end of RT

| | |
|---|---|
| Assessment type | Non-systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 19.0 |

### Reporting groups

| | |
|---|---|
| Reporting group title | Adverse events |

Reporting group description: -

| Serious adverse events | Adverse events | | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | 0 | | |
| Immune system disorders | | | |
| Anaphylactic reaction | Additional description: Anaphylactic reaction | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Adverse events | | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 14 / 14 (100.00%) | | |
| Vascular disorders | | | |
| Hot flush | Additional description: Hot flush | | |
| subjects affected / exposed | 4 / 14 (28.57%) | | |
| occurrences (all) | 7 | | |
| Lymphoedema | Additional description: Lymphoedema | | |
| subjects affected / exposed | 4 / 14 (28.57%) | | |
| occurrences (all) | 5 | | |
| Surgical and medical procedures | | | |

| | | | |
|---|---|---|---|
| Glaucoma surgery | Additional description: Glaucoma surgery | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| **General disorders and administration site conditions** | | | |
| Asthenia | Additional description: Asthenia | | |
| subjects affected / exposed | 11 / 14 (78.57%) | | |
| occurrences (all) | 25 | | |
| Mucosal inflammation | Additional description: Mucosal inflammation | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Oedema peripheral | Additional description: Oedema peripheral | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Pyrexia | Additional description: Pyrexia | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 3 | | |
| **Reproductive system and breast disorders** | | | |
| Breast haematoma | Additional description: Breast haematoma | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Dyspareunia | Additional description: Dyspareunia | | |
| subjects affected / exposed | 3 / 14 (21.43%) | | |
| occurrences (all) | 3 | | |
| Intermenstrual bleeding | Additional description: Intermenstrual bleeding | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Menopausal symptoms | Additional description: Menopausal symptoms | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Pelvic pain | Additional description: Pelvic pain | | |
| subjects affected / exposed | 4 / 14 (28.57%) | | |
| occurrences (all) | 4 | | |
| Rectocele | Additional description: Rectocele | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Uterine fibrosis | Additional description: Uterine fibrosis | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Vaginal discharge | Additional description: Vaginal discharge | | |
| subjects affected / exposed | 3 / 14 (21.43%) | | |
| occurrences (all) | 4 | | |
| Vaginal haemorrhage | Additional description: Vaginal haemorrhage | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Vulvovaginal dryness | Additional description: Vulvovaginal dryness | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Vulvovaginal swelling | Additional description: Vulvovaginal swelling | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | Additional description: Cough | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Dyspnoea | Additional description: Dyspnoea | | |
| subjects affected / exposed | 3 / 14 (21.43%) | | |
| occurrences (all) | 4 | | |
| Psychiatric disorders | | | |
| Sleep disorder | Additional description: Sleep disorder | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Investigations | | | |
| Blood folate decreased | Additional description: Blood folate decreased | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Eosinophil count increased | Additional description: Eosinophil count increased | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Transaminases increased | Additional description: Transaminases increased | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 3 | | |
| Injury, poisoning and procedural complications | | | |

| | | | |
|---|---|---|---|
| Compression fracture | Additional description: Compression fracture | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Contusion | Additional description: Contusion | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Face injury | Additional description: Face injury | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Fracture | Additional description: Fracture | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Pelvic fibrosis | Additional description: Pelvic fibrosis | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Nervous system disorders | | | |
| Dizziness | Additional description: Dizziness | | |
| subjects affected / exposed | 3 / 14 (21.43%) | | |
| occurrences (all) | 3 | | |
| Dysgeusia | Additional description: Dysgeusia | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Headache | Additional description: Headache | | |
| subjects affected / exposed | 4 / 14 (28.57%) | | |
| occurrences (all) | 4 | | |
| Hypoaesthesia | Additional description: Hypoaesthesia | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Neuropathy peripheral | Additional description: Neuropathy peripheral | | |
| subjects affected / exposed | 11 / 14 (78.57%) | | |
| occurrences (all) | 25 | | |
| Paraesthesia | Additional description: Paraesthesia | | |
| subjects affected / exposed | 5 / 14 (35.71%) | | |
| occurrences (all) | 5 | | |
| Sciatica | Additional description: Sciatica | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Syncope | Additional description: Syncope | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Taste disorder | Additional description: Taste disorder | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Uraemic neuropathy | Additional description: Uraemic neuropathy | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | Additional description: Anaemia | | |
| subjects affected / exposed | 13 / 14 (92.86%) | | |
| occurrences (all) | 37 | | |
| Hyperleukocytosis | Additional description: Hyperleukocytosis | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Lymphopenia | Additional description: Lymphopenia | | |
| subjects affected / exposed | 12 / 14 (85.71%) | | |
| occurrences (all) | 24 | | |
| Neutropenia | Additional description: Neutropenia | | |
| subjects affected / exposed | 7 / 14 (50.00%) | | |
| occurrences (all) | 16 | | |
| Thrombocytopenia | Additional description: Thrombocytopenia | | |
| subjects affected / exposed | 8 / 14 (57.14%) | | |
| occurrences (all) | 11 | | |
| Ear and labyrinth disorders | | | |
| Deafness | Additional description: Deafness | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Hypoacusis | Additional description: Hypoacusis | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Tinnitus | Additional description: Tinnitus | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Eye disorders | | | |
| Vision blurred | Additional description: Vision blurred | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Visual field defect | Additional description: Visual field defect | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Gastrointestinal disorders | | | |
| Abdominal distension | Additional description: Abdominal distension | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Anal incontinence | Additional description: Anal incontinence | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Burn oesophageal | Additional description: Burn oesophageal | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Constipation | Additional description: Constipation | | |
| subjects affected / exposed | 5 / 14 (35.71%) | | |
| occurrences (all) | 6 | | |
| Diarrhoea | Additional description: Diarrhoea | | |
| subjects affected / exposed | 10 / 14 (71.43%) | | |
| occurrences (all) | 16 | | |
| Abdominal pain | Additional description: Abdominal pain | | |
| subjects affected / exposed | 5 / 14 (35.71%) | | |
| occurrences (all) | 11 | | |
| Flatulence | Additional description: Flatulence | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Gastrooesophageal reflux disease | Additional description: Gastrooesophageal reflux disease | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 2 | | |
| Haemorrhoids | Additional description: Haemorrhoids | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Nausea | Additional description: Nausea | | |
| subjects affected / exposed | 7 / 14 (50.00%) | | |
| occurrences (all) | 22 | | |
| Odynophagia | Additional description: Odynophagia | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Vomiting | Additional description: Vomiting | | |
| subjects affected / exposed | 5 / 14 (35.71%) | | |
| occurrences (all) | 11 | | |
| Proctitis | Additional description: Proctitis | | |
| subjects affected / exposed | 3 / 14 (21.43%) | | |
| occurrences (all) | 3 | | |
| Toothache | Additional description: Toothache | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | Additional description: Alopecia | | |
| subjects affected / exposed | 7 / 14 (50.00%) | | |
| occurrences (all) | 8 | | |
| Dry skin | Additional description: Dry skin | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Pain of skin | Additional description: Pain of skin | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Telangiectasia | Additional description: Telangiectasia | | |
| subjects affected / exposed | 6 / 14 (42.86%) | | |
| occurrences (all) | 6 | | |
| Renal and urinary disorders | | | |
| Dysuria | Additional description: Dysuria | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Incontinence | Additional description: Incontinence | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 2 | | |
| Nocturia | Additional description: Nocturia | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Urinary incontinence | Additional description: Urinary incontinence | | |
| subjects affected / exposed | 3 / 14 (21.43%) | | |
| occurrences (all) | 3 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | Additional description: Arthralgia | | |
| subjects affected / exposed | 3 / 14 (21.43%) | | |
| occurrences (all) | 4 | | |
| Back pain | Additional description: Back pain | | |
| subjects affected / exposed | 3 / 14 (21.43%) | | |
| occurrences (all) | 4 | | |
| Muscle spasms | Additional description: Muscle spasms | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Myalgia | Additional description: Myalgia | | |
| subjects affected / exposed | 6 / 14 (42.86%) | | |
| occurrences (all) | 6 | | |
| Neck pain | Additional description: Neck pain | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Pain in extremity | Additional description: Pain in extremity | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Infections and infestations | | | |
| Covid-19 | Additional description: Covid-19 | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Cystitis | Additional description: Cystitis | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Gastroenteritis | Additional description: Gastroenteritis | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Genital infection | Additional description: Genital infection | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Nasopharyngitis | Additional description: Nasopharyngitis | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Urinary tract infection | Additional description: Urinary tract infection | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Metabolism and nutrition disorders | | | |
| Cell death | Additional description: Cell death | | |
| subjects affected / exposed | 2 / 14 (14.29%) | | |
| occurrences (all) | 2 | | |
| Decreased appetite | Additional description: Decreased appetite | | |
| subjects affected / exposed | 3 / 14 (21.43%) | | |
| occurrences (all) | 3 | | |
| Hypoglycaemia | Additional description: Hypoglycaemia | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |
| Iron deficiency | Additional description: Iron deficiency | | |
| subjects affected / exposed | 1 / 14 (7.14%) | | |
| occurrences (all) | 1 | | |

## More information

## Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 04 March 2020 | Protocol, and synopsis:<br>•Modification of the delay between the baseline assessments and inclusion in Part 1, going from 7 days to 28 days. The biological assessment must be carried out within 7 days before the start of treatment.<br>•Modification of gynecological monitoring: it will not be requested at each visit during the treatment cycles: these examinations must be carried out at baseline, before the start of Part 2 and at the end of the study (at the end of treatment) and when necessary<br>•Pregnancy tests: this test remains necessary at baseline for validation of inclusion, it will then no longer be carried out automatically and mandatory at other times of the study, because the sterilizing effect of radiotherapy is recognized.<br>•Modification of an inclusion criterion for Part 2: "Patients who received chemotherapy + concomitant boost on macroscopic lymph nodes" modified by "Patients who received chemotherapy that can be associated with a concomitant boost on macroscopic lymph nodes." » Because not all patients will receive this boost since it depends on the presence or not of lymph nodes visible macroscopically on the PET scan.<br>•Concomitant treatments: it is added that treatment with EPO is not recommended.<br>•Modification of an inclusion criterion for Part 2: "Patients who received chemotherapy + concomitant boost on macroscopic lymph nodes" is replaced by "Patients who received chemotherapy that can be associated with a concomitant boost on macroscopic lymph nodes." », because not all patients will receive this boost since it depends on the presence or not of lymph nodes visible macroscopically on the PET scan<br>•Concomitant treatments: it is added that treatment with EPO is not recommended.<br><br>Trial site list:<br>•Declaration of 3 new investigators for site n°1 (Centre Oscar Lambret, Lille)<br><br>Informed consent form:<br>•Conduct of the study: modification of the duration of the assessment planned for inclusion in Part 1, going from 7 days |
| 27 March 2020 | • Temporary halt of inclusions on 27-MAR-2020 due to the health situation linked to Covid-19<br>• Restart of inclusions on 26-MAY-2020 in the conditions prior to the transitional measures linked to Covid-19 |
| 23 February 2021 | Trial site list:<br>• Declaration of a new investigator for site n°1 (Centre Oscar Lambret, Lille)<br>• Addition of a 6th trial site: Lens Hospital Center, represented by Dr. FOURQUET as principal investigator |

| | |
|---|---|
| 14 June 2021 | Protocol, and synopsis:<br>• Addition of recommendations linked to the anti-COVID vaccine strategy<br><br>Trial site lists:<br>•Declaration of a new investigator for site n°2 (Centre Léonard de Vinci)<br><br>SmPC PACLITAXEL 6mg/ml:<br>•Update of the document (version of 14-JUNE-2021), with the description of a new adverse event of undetermined frequency: palmoplantar erythrodysesthesia which may persist beyond 6 months after stopping treatment. This modification has an impact on the expected/unexpected nature of the SARs and the conduct of the study; it is therefore considered substantial but does not require an update of the protocol (this already specifies the action to be taken in the event of peripheral neuropathies) nor the informed consent form given to patients (which already includes the list of frequent and very frequent adverse effects) |
| 21 November 2022 | Protocol, and synopsis:<br>•Extension of the recruitment period by 6 months and update of the study schedule. The duration of exposure to the investigational drug is not extended, the definition of the end of the trial and the monitoring conditions are unchanged. At the end of this extension, the study will be definitively closed to recruitment.<br><br>Protocol:<br>•Compliance of the protocol with the SPC of paclitaxel dated 04-MAR-2021: addition of new contraindicated combinations with paclitaxel<br><br>Informed consent form:<br>•Information on the recruitment period is deleted because it is calculated on the total number of patients initially expected, however, the objective is now to reach 50% of inclusions (23 patients) by 30-JUNE-2023.<br>•Information on the delay necessary to obtain results is also removed, for the same reasons as above.<br>•Addition of a safety instruction related to the contraceptive method.<br>•Addition of a paragraph to allow the reuse of data for other research (retrospective cohorts, etc.)<br>•Update of the CNIL URL to allow patients to send a complaint to the CNIL; the postal address is also specified<br><br>SmPC PACLITAXEL 6mg/ml<br>•Update of the document (version of 04-MAR-2021). Some of the modifications have an impact on the list of concomitant treatments to avoid<br>•Addition of contraindicated combinations of palitaxel with St. John's wort, live attenuated vaccines;<br>•Addition of associations not recommended with new enzyme inducers not described in the previous version of the SPC) and fosphenytoin). |
| 20 June 2025 | Protocol and synopsis:<br>•The follow-up of patients is interrupted on 31-JAN-2025 (=LPLV)<br>•Addition of a paragraph regarding the modification of the end of the trial, and its justification<br>•Compliance of the duration of follow-up with the end of the study<br>New document:<br>•Introduction of a new letter to inform patients of the end of the study<br><br>Insurance:<br>•The insurance certificate is updated following the new definition of end of study<br><br>Note:<br>This substantial amendment was released for information to regulatory authorities since the trial had already been completed, and because the platform for submitting amendments to the french Ethics Committee (SI RIPH 2G) does not allow to submit amendment after the end of the study. However, the Ethics Committee received and examined the documents outside the usual procedure and made a comment on the information letter. All modifications requested by the Ethics Committee regarding the information letter have been made. |

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial?  Yes

| Date | Interruption | Restart date |
|---|---|---|
| 27 March 2020 | Temporary discontinuation (Covid), then permanent discontinuation because recruitment targets were very difficult to achieve with only two active sites (four of the six sites opened did not include any patients). | 26 May 2020 |

Notes:

## Limitations and caveats

None reported